GlassScriptPhysician profile
Susan Roth Wilton
NPI 1851370407
$695.71
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $105 · 2021: $206 · 2022: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $131.93 | 2019-2021 | |
| Allergan, INC. | $117.92 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $71.19 | 2019-2022 | |
| Oyster Point Pharma, INC. | $53.97 | 2022 | |
| Horizon Therapeutics Plc | $51.31 | 2021 | |
| Kala Pharmaceuticals, INC. | $46.22 | 2021 | |
| Carl Zeiss Meditec, INC. | $22.16 | 2019 | |
| Tearlab Corp | $22.12 | 2019 | |
| Abbvie INC. | $21.82 | 2022 | |
| Quidel Corporation | $21.36 | 2022 | |
| Omeros Corporation | $17.83 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $17.44 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.15 | 2019 | |
| Oasis Medical, INC. | $10.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Wilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.